Tempus was co-founded in 2015 by Eric Lefkofksy (who also acts as a the company’s Chief Executive Officer) with the mission to improve cancer patient outcomes by using data-driven and software insights. Tempus is attempting to advance precision medicine by collecting and analyzing clinical and molecular data, building the largest library in the world and making data accessible through an operating system. In the three years since its inception, Tempus managed to build the most comprehensive set of data in the industry, with the help of collaborators and clinical partners throughout the United States.
By using AI-assisted image recognition, next-generation sequencing, and advance machine learning, Tempus’s platform accelerates new discovery and insights, and is able to help thousands of physicians make real time decisions based on data on behalf of their patients. Tempus has built a series of data pipelines in order to collect, analyze and cleanse data. Eric Lefkofsky noted that the company’s mission is to help usher in precision medicine, both in the United States and abroad. He also mentioned that they are thrilled with the progress they made and are honored to be surrounded by world class collaborators, partners and investors.
Tempus has an active partnership with hospital networks, community physicians across the nation, leading academic medical centers, and the American Society of Clinical Oncologists. They collaborate with hospitals such as Mayo Clinic, University of Chicago Medicine, University of Michigan, Cleveland Clinic, and many more. As a result, the Tempus platform reaches close to 1 in 4 cancer patients in the country. The company has announced that it has raised a $110 million Series E, which puts the total funding at $320 million, making it one of the fastest growing tech companies in Chicago. The funds will be used to expand into new therapeutic areas and grow operations.